Paclitaxel targets the spindle assembly checkpoint (SAC), a quality-control mechanism that operates during mitosis. By preventing the cell’s internal scaffolding from working properly, paclitaxel locks dividing cells in mitosis and ultimately drives them toward death. This is the primary reason it remains one of the most widely used chemotherapy drugs.
The Spindle Assembly Checkpoint, Explained
Every time a cell divides, it must split its duplicated chromosomes evenly between two daughter cells. The spindle assembly checkpoint exists to make sure this happens correctly. It acts as a stop signal during mitosis, halting the process at the transition between metaphase and anaphase until every chromosome is properly attached to the spindle fibers that will pull them apart.
The checkpoint relies on a group of sensor proteins, including Mad1, Mad2, BubR1, Bub1, Bub3, and MPS1. Among these, Mad2 and BubR1 play the most central roles. When they detect even a single unattached or improperly attached chromosome, they block the activation of a large protein complex called the anaphase-promoting complex (APC/C). The APC/C is essentially the “go” signal for cell division to proceed. As long as the checkpoint keeps it turned off, the cell stays frozen in mitosis.
How Paclitaxel Triggers the Checkpoint
Paclitaxel belongs to a class of drugs called microtubule-targeting agents. Microtubules are the structural fibers that form the spindle apparatus during cell division. Normally, these fibers are dynamic: they grow and shrink rapidly as they search for and attach to chromosomes. Paclitaxel binds to a specific pocket on the beta-tubulin subunit of microtubules and locks them into a stable, rigid state. This prevents the normal shrinking and growing cycle the spindle needs to function.
With the spindle unable to properly attach to all chromosomes, the spindle assembly checkpoint stays permanently activated. The sensor proteins continuously signal that something is wrong, and the APC/C never gets the green light. The cell remains stuck in mitosis, unable to proceed to the final stages of division. This chronic activation of the checkpoint is what makes paclitaxel effective against rapidly dividing cancer cells.
What Happens to Arrested Cells
Once a cell is trapped in mitosis by paclitaxel, two competing processes determine its fate. One pathway accumulates pro-death signals the longer the cell sits in mitotic arrest. The other pathway slowly degrades a key protein called cyclin B, which can eventually allow the cell to slip out of mitosis without dividing, a process called mitotic slippage.
In most cases, the pro-death signals win. Research on cancer cell lines shows that paclitaxel causes significant cell death within 24 hours, often through a process called mitotic catastrophe. Cells that do slip out of mitosis typically become abnormal multinucleated cells (containing more than one nucleus). These escapees generally arrest again at the G2/M phase and trigger cell death within 48 hours as their regulatory proteins break down. Either way, the outcome for the cell is usually fatal.
Dose Changes the Mechanism
Paclitaxel’s effects on the cell cycle are not identical at every concentration. At low doses (roughly 0.01 to 0.1 µM in lab settings), the drug suppresses microtubule dynamics just enough to disrupt spindle formation, producing a clean G2/M arrest through the spindle assembly checkpoint. This is the classic mechanism described above.
At higher concentrations, the picture changes. Massive microtubule damage activates additional stress-signaling pathways that can trigger cell death independently of mitotic arrest. This means that at high doses, paclitaxel can kill cells regardless of which phase of the cell cycle they happen to be in, not just those actively dividing. The clinical implication is that paclitaxel’s cancer-killing ability involves checkpoint-dependent arrest at therapeutic doses, with broader toxicity at higher exposures.
How Cancer Cells Develop Resistance
Because paclitaxel’s effectiveness depends on activating the spindle assembly checkpoint, cancer cells that find ways to weaken or bypass this checkpoint can survive treatment. Several resistance mechanisms have been identified. Some tumors develop mutations in beta-tubulin, the exact protein paclitaxel binds to, which reduces the drug’s ability to stabilize microtubules. Others upregulate molecular pumps that actively push the drug out of the cell before it can reach its target.
A third route involves changes to the proteins that control apoptosis. If a cancer cell’s death machinery is impaired, even a prolonged mitotic arrest may not generate enough pro-death signaling to kill it. The cell can then slip out of mitosis and continue growing. Research into these resistance pathways has focused on strategies to extend the duration of mitotic arrest or block the slippage escape route, making the checkpoint harder for cancer cells to outlast.